Commercial Phase Negotiations Sample Clauses

Commercial Phase Negotiations. Within thirty (30) days after completion of Milestone 2 under the Development Phase, the parties shall for a period of at least sixty (60) days enter into good faith negotiations for the supply of BMIPP to Molecular Insight Pharmaceuticals, during the Commercial Phase.
Sample 1Sample 2
AutoNDA by SimpleDocs
Commercial Phase Negotiations. Within thirty (30) days after completion of milestone 2 under the Development Phase, the parties shall for a period of at least sixty (60) days enter into good faith negotiations for the supply of Altropane to BLSI, during the Commercial Phase. Indicative pricing for the supply of Altropane is anticipated to be the order of (CONFIDENTIAL TREATMENT REQUESTED)This pricing does not include shipping costs. Actual pricing will be subject to good faith negotiations of a Commercial Phase Supply agreement, it being understood that the foregoing price reflects a radiolabelling yield of 90, batch sizes containing a minimum of 100 doses and an Altropane dose containing 5 mCi of Isotope at noon on the day of use. It is acknowledged that if, during the initial stage of commercial introduction of Altropane, the minimum 20,000 annual doses and/or 90% yield and/or batch size requirements are not met, the negotiation of Commercial Phase pricing shall take such factors into account in determining price.
Sample 1
Commercial Phase Negotiations. Within thirty (30) days after completion of milestone 2 under the Development Phase, the parties shall for a period of at least sixty (60) days enter into good faith negotiations for the supply of Altropane to BLSI, during the Commercial Phase. Indicative pricing for the supply of Altropane is anticipated to be the order of (CONFIDENTIAL TREATMENT REQUESTED)This pricing does not include shipping costs. Actual pricing will be subject to good faith negotiations of a Commercial Phase Supply agreement, it being understood that the foregoing price reflects a radiolabelling yield of 90, batch sizes containing a minimum of 100 doses and an Altropane dose containing 5 mCi of Isotope at noon on the day of use (CONFIDENTIAL TREATMENT REQUESTED)
Sample 1

Related to Commercial Phase Negotiations

  • Development Phase contractual phase initiated with the approval of ANP for the Development Plan and which is extended during the Production Phase while investments in xxxxx, equipment, and facilities for the Production of Oil and Gas according to the Best Practices of the Oil Industry are required.

  • Commercial Diligence Upon execution of this Agreement, Licensee shall diligently proceed with Commercially Diligent Efforts to develop, manufacture, practice, sell and use the Licensed Products in order to make them readily available to the general public as soon as possible on commercially reasonable terms. Licensee shall continue active, diligent Commercially Diligent Efforts for one or more Licensed Product(s) throughout the term of this Agreement (“Actively Commercializing”). In addition, Licensee shall perform at least the following obligations as part of its due diligence activities hereunder:

  • Development Period The Contractor may commence pre-construction activities like utility shifting, boundary wall construction or any other activity assigned to the Contractor by the Authority to enable construction of the Project Highway immediately after signing of the Agreement, to the extent that such work is ready for execution. The Parties agree that these works may be taken up and completed to the extent feasible by the Contractor, before declaration of the Appointed Date, but no claim against the Authority for delay shall survive during this period and that the undertaking of these works by the Contractor shall not count towards the Scheduled Construction Period of the project which starts counting only from the Appointed Date. No construction activity of the Project Highway shall be undertaken during the development period.

  • Production Phase contract period in which the Development and the Production are to be performed.

  • Design Development Phase INDICATE IN STATEMENT OF WORK “NOT APPLICABLE” IF SECTION IS NOT APPLICABLE

  • Development Program A. Development activities to be undertaken (Please break activities into subunits with the date of completion of major milestones)

  • Development Diligence Novartis shall dedicate commercially reasonable efforts, during each [**] month period, necessary to continue the advancement of Licensed Compounds and Licensed Products with respect to at least one Profile towards the next clinical Development milestone or approval milestone, as described in Sections 7.4.2 or 7.4.3, respectively. If Novartis (itself or through its Affiliates or sublicensees) fails to dedicate commercially reasonable efforts, during any [**] month period, necessary to continue the advancement of Licensed Compounds and Licensed Products with respect to at least one Profile towards such next milestone, then any dispute regarding Novartis’ failure of development diligence with respect to such Profile shall be resolved in accordance with Article 13.

  • Construction Phase Services 3.1.1 – Basic Construction Services

  • Development Efforts Genentech will use commercially reasonable and diligent efforts to develop C2B8, including pursuing preclinical development and clinical development of C2B8 and obtaining Regulatory Approvals therefor in all countries in the Licensed Territory, taking into account the scientific and commercial potential of C2B8, including, without limitation, each of the potential indications in the Field for C2B8. Within ninety (90) days of the Original Effective Date, Genentech agrees to provide IDEC with a written development strategy for C2B8 in the Licensed Territory indicating (i) whether Genentech will develop C2B8 alone or with a partner in Europe, (ii) the identity of its European partner (if any), and (iii) a list of clinical trials which Genentech would conduct for C2B8 approval in Europe assuming adequate quantities of C2B8 are available.

  • Synchronization, Commissioning and Commercial Operation 4.1.1 The Power Producer shall give at least thirty (30) days written notice to the SLDC and GUVNL, of the date on which it intends to synchronize the Power Project to the Grid System.

Time is Money Join Law Insider Premium to draft better contracts faster.